Drug Trial Radar · NCT02499835
Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer
Last checked: Nov 19, 2026Latest source record: Aug 1, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
66
Actual
Start
Jul 1, 2015
Primary completion
Aug 9, 2021
Study completion Jul 27, 2023
Sponsor
- Lead sponsor
- University of Wisconsin, MadisonAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Prostate Cancer Foundation; Madison Vaccines Incorporated
- First posted
- Jul 16, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomized pilot trial studies vaccine therapy and pembrolizumab in treating patients with prostate cancer that does not respond to treatment with hormones (hormone-resistant) and has spread to other places in the body (metastatic). Vaccines made from deoxyribonucleic acid (DNA), such as pTVG-HP plasmid DNA vaccine, may help the body build an effective immune response to kill tumor cells. Monoclonal antibodies, such as pembrolizumab, may find tumor cells and help kill them. Giving pTVG-HP plasmid DNA vaccine and pembrolizumab may kill more tumor cells.
Conditions
- Hormone-Resistant Prostate Cancer
- Metastatic Malignant Neoplasm in the Bone
- Metastatic Malignant Neoplasm in the Soft Tissues
- Metastatic Prostate Carcinoma
- Prostate Adenocarcinoma
- Recurrent Prostate Carcinoma
- Stage IV Prostate Cancer
Interventions
PembrolizumabBiological
Given IV
pTVG-HP Plasmid DNA VaccineBiological
Given ID
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Adverse Events, Using the National Cancer Common Terminology Criteria, Version 4Time frame: Up to 23 months (Up to 12 months after completion of study treatment)
- 6-month Progression Free Survival RateTime frame: 6 months
- Median Time to Radiographic ProgressionTime frame: Up to 2 years
- Number of Participants Who Have an Objective ResponseTime frame: Up to 2 years
- Number of Participants Who Have a PSA ResponseTime frame: Up to 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.